Although the efficacy of the addition of ipratropium bromide (IB) to short-acting β2-agonists (SABAs) for treating children with moderate to severe asthma exacerbations has been demonstrated, evidence of its cost-effectiveness is scarce. The aim of the present study was to evaluate the cost-effectiveness of treatment with a combination of SABAs and IB compared with SABAs alone for the treatment of children with moderate to severe asthma exacerbations.

中文翻译：

---

使用异丙托溴铵在紧急情况下治疗儿科患者的中度至重度哮喘发作：成本效益分析

尽管已证明将异丙托溴铵 (IB) 添加到短效 β2-激动剂 (SABA) 中治疗中重度哮喘发作儿童的疗效，但其成本效益的证据很少。本研究的目的是评估 SABAs 和 IB 联合治疗与单独 SABAs 相比治疗中度至重度哮喘发作儿童的成本效益。